Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

2016241 citationsJournal Articlegreen Open Access

Authors

Nick Pavlakis · Saint John's Hospital

Katrin Marie Sjoquist · Saint John's Hospital

Andrew Martin · Saint John's Hospital

Eric Tsobanis · Saint John's Hospital

Sonia Yip · Saint John's Hospital

Yoon‐Koo Kang · Saint John's Hospital

Yung‐Jue Bang ·

Abstract

In this phase II trial, regorafenib was effective in prolonging PFS in refractory advanced gastric adenocarcinoma. Regional differences were found, but regorafenib was effective in both regional groups. A phase III trial is planned.

Topics & Keywords

Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies Helicobacter pylori-related gastroenterology studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 34, Issue 23, pp. 2728-2735

DOI: 10.1200/jco.2015.65.1901

Field-Weighted Citation Impact: 23.32